Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Barriers for vaccination of healthcare workers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effects of risk factors for ovarian cancer in women with and without endometriosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Human Papillomavirus Infection Among Pregnant Women Living With HIV: A Systematic Review and Meta-Analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Mari Nygård
  • Bo T Hansen
  • Susanne K Kjaer
  • Maria Hortlund
  • Laufey Tryggvadóttir
  • Christian Munk
  • Camilla Lagheden
  • Lara G Sigurdardottir
  • Suzanne Campbell
  • Kai-Li Liaw
  • Joakim Dillner
Vis graf over relationer

Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18-51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4-5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5-16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5-15.4), with PPV of 8.0% (95% CI: 6.8-9.3) and OR 23.7 (95% CI: 16.0-63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8-9.2) with PPV of 4.4% (95% CI: 3.3-5.7) and OR of 2.9 (95% CI: 2.0-4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1-3.9), and OR 1.5 (95% CI: 1.1-2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits.

OriginalsprogEngelsk
TidsskriftHuman vaccines & immunotherapeutics
Vol/bind17
Udgave nummer4
Sider (fra-til)972-981
Antal sider10
ISSN2164-5515
DOI
StatusUdgivet - 3 apr. 2021

ID: 61555505